| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Nové doklady naznačují, že subpopulace buněk v nádoru má vlastnosti podobné kmenovým buňkám. Tyto buňky iniciující nádory, odlišné od nemaligních kmenových buněk, vykazují nízkou proliferativní rychlost, vysokou schopnost sebeobnovování, přirozený sklon k diferenciaci na dělící se nádorové buňky, resistenci k chemoterapii nebo ozáření a jsou často charakterizovány zvýšenou expresí povrchové značky kmenových buněk CD133. Porozumění molekulární biologii CD133+ rakovinných buněk je nyní nezbytné pro vývoj účinnějších protirakovinných přístupů. Mezi nimi je zahrnuto působení látkami zasahujícími organely (mitochondrie, lysosomy), včetně vysoce účinných a selektivních induktorů apoptózy. Rovněž jsou zajímavá léčiva či režimy léčby, které zvyšují citlivost těchto %22nádorových kmenových%22 buněk vzdorujících terapii k již užívaným či teprve vyvíjeným protirakovinným lékům. (cs)
- Recent evidence suggests that a subset of cells within a tumour have %22stem-like%22 characteristics. These tumour-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumour cells, resistance to chemotherapy or radiation, and they are often characterised by elevated expression of the stem cell surface marker CD133. Understanding the molecular biology of the CD133+ cancer cells is now essential for developing more effective cancer treatments. These may include drugs targeting organelles, such as mitochondria or lysosomes, using highly efficient and selective inducers of apoptosis. Alternatively, agents or treatment regimens that enhance sensitivity of these therapy-resistant %22tumour stem cells%22 to the current or emerging anti-tumour drugs would be of interest as well.
- Recent evidence suggests that a subset of cells within a tumour have %22stem-like%22 characteristics. These tumour-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumour cells, resistance to chemotherapy or radiation, and they are often characterised by elevated expression of the stem cell surface marker CD133. Understanding the molecular biology of the CD133+ cancer cells is now essential for developing more effective cancer treatments. These may include drugs targeting organelles, such as mitochondria or lysosomes, using highly efficient and selective inducers of apoptosis. Alternatively, agents or treatment regimens that enhance sensitivity of these therapy-resistant %22tumour stem cells%22 to the current or emerging anti-tumour drugs would be of interest as well. (en)
|
| Title
| - Tumour-initiating cells vs. cancer %22stem%22 cells and CD133: What's in the name?
- Buňky iniciující nádory či rakovinné %22kmenové%22 buňky a CD133: co je po jméně? (cs)
- Tumour-initiating cells vs. cancer %22stem%22 cells and CD133: What's in the name? (en)
|
| skos:prefLabel
| - Tumour-initiating cells vs. cancer %22stem%22 cells and CD133: What's in the name?
- Buňky iniciující nádory či rakovinné %22kmenové%22 buňky a CD133: co je po jméně? (cs)
- Tumour-initiating cells vs. cancer %22stem%22 cells and CD133: What's in the name? (en)
|
| skos:notation
| - RIV/68378050:_____/07:00096517!RIV08-AV0-68378050
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - Z(AV0Z50520514), Z(AV0Z50520701), Z(MZE0002716201)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/07:00096517
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - tumour-initiating cells; CD133; resistance to treatment (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Biochemical and Biophysical Research Communications
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Anděra, Ladislav
- Neužil, Jiří
- Ralph, S. J.
- Stantic, M.
- Zobalová, Renata
- Dong, L.
- Procházka, L.
- Wang, X. F.
- Chladová, Miroslava
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)